Russell J. Butterfield | University of ...

Dr. Russell Butterfield, MD, PhD

Claim this profile

University of Utah

Studies Duchenne Muscular Dystrophy
Studies Myelodysplastic Syndrome
6 reported clinical trials
8 drugs studied

Area of expertise

1Duchenne Muscular Dystrophy
Russell Butterfield, MD, PhD has run 3 trials for Duchenne Muscular Dystrophy. Some of their research focus areas include:
dystrophin positive
DMD negative
DMD positive
2Myelodysplastic Syndrome
Russell Butterfield, MD, PhD has run 3 trials for Myelodysplastic Syndrome. Some of their research focus areas include:
DMD negative
DMD positive

Affiliated Hospitals

Image of trial facility.
University Of Utah
Image of trial facility.
University Of Utah Hospital

Clinical Trials Russell Butterfield, MD, PhD is currently running

Image of trial facility.

Zolgensma

for Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.
Recruiting1 award N/A2 criteria
Image of trial facility.

Motor Outcomes Evaluation

for Facioscapulohumeral Muscular Dystrophy

The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and reachable workspace, as well as optional muscle biopsy and wearable device (US participants only).
Recruiting1 award N/A1 criteria

More about Russell Butterfield, MD, PhD

Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Russell Butterfield, MD, PhD has experience with
  • Placebo
  • DYNE-251
  • Motor Outcomes To Validate Evaluations In FSHD (MOVE FSHD)
  • CAP-1002
  • Prospective Observational Registry
  • Zolgensma

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Russell Butterfield, MD, PhD specialize in?
Is Russell Butterfield, MD, PhD currently recruiting for clinical trials?
Are there any treatments that Russell Butterfield, MD, PhD has studied deeply?
What is the best way to schedule an appointment with Russell Butterfield, MD, PhD?
What is the office address of Russell Butterfield, MD, PhD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security